Price/Sales of Retrophin, Inc.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|BTX BioTime, Inc.||NYSEMKT > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||3.86|
|RADA RADA Electronic Industries Ltd.||NASDAQ > Consumer Non-Durables > Electronic Components||3.87|
|CRUS Cirrus Logic, Inc.||NASDAQ > Technology > Semiconductors||3.87|
|TXN Texas Instruments Incorporated||NASDAQ > Technology > Semiconductors||3.87|
|ARWR Arrowhead Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.87|
|LPTH LightPath Technologies, Inc.||NASDAQ > Technology > Semiconductors||3.88|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.88|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||297.63|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||762.43|
|WMIH WMIH Corp.||NASDAQ > Finance > Finance: Consumer Services||812.31|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||966.10|
|HUNT Hunter Maritime Acquisition Corp.||NASDAQ > Transportation > Oil Refining/Marketing||1,687.50|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|